In this issue of Blood, Wu et al describe the molecular function of HFE, the gene most commonly mutated in hereditary hemochromatosis (HH).
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H is a potentially fatal disorder hallmarked by dietary iron hyperabsorption, hyperferremia, and tissue iron overload. Complications include liver cirrhosis, cancer, diabetes, heart failure, and arthritis that can be prevented by phlebotomy. All family studies identified homozygous missense mutations of the HFE gene (C282Y) occurring in the most common HH subtype. 2 Wild-type HFE encodes a ubiquitously expressed major histocompatibility complex class 1-like molecule (MHC-1). Of note, the aforementioned point mutation inhibits binding of b2-microglobulin (b2M) and HFE cell-surface expression. Although HFE was discovered almost 20 years ago, its molecular function remained unknown. Less common but clinically more severe forms of HH are caused by mutations in hemojuvelin (HJV), transferrin receptor 2 (TfR2), or hepcidin (HAMP). Most probably, regulated protein/protein interactions among the membrane proteins HFE, TfR2, and HJV in hepatocytes integrate signals elicited by the concentration of iron-bound transferrin and hepatocytic iron stores, which ultimately control the expression of hepcidin. This iron hormone is secreted by hepatocytes and binds to the iron exporter ferroportin to suppress dietary iron uptake and iron release from iron-recycling macrophages. These HH subtypes show unphysiologic low hepcidin levels, which explains increased dietary iron uptake and systemic iron accumulation in these patients. 3 The mechanism by which iron-bound transferrin is sensed by hepatocytes to control hepcidin transcription is not fully understood. In turn, activated BMP type I receptors phosphorylate receptor-associated SMAD proteins (R-SMADs). These signaling molecules transfer together with SMAD4 to the hepatocyte nucleus to induce hepcidin transcription. Importantly, the BMP/SMAD signaling pathway is impaired in patients with HFE-HH, 10 as well as in homozygous
Hfe-deficient mice, suggesting a crucial role of HFE in BMP/SMAD signaling. The present study by Wu et al provides novel and critical molecular insights into how HFE connects to BMP/SMAD signaling. In their elegant work, this group shows that HFE binds to the BMP type I receptor Alk3 in both cultured hepatocytes and mouse liver. Upon binding, Alk3 protein is stabilized on the hepatocyte's cell surface. By applying Regulated protein-protein interactions among HFE, TfR2, HJV (proteins mutated in HH), BMP receptors, and BMP ligands play a critical role in the "sensing" of transferrin-bound Fe to control hepcidin expression in hepatocytes. HFE binds to BMP receptor type I (Alk3) to prevent its ubiquitination and proteasomal degradation. As a result, expression of ALK3 is increased on the cell surface, activating BMP/SMAD signaling and hepcidin transcription. Professional illustration by Tom Webster, Lineworks, Inc.
pharmacologic inhibitors, the authors show that HFE binding to ALK3 diminishes polyubiquitination of Alk3 and thus its degradation via the proteasome. Consistent with this finding in cultured cells, Alk3 protein levels are reduced in mice lacking HFE, whereas Alk3 mRNA levels are not altered. The authors further analyze how the 2 most common polymorphisms in the HFE gene (C282Y and H63D) affect BMP/SMAD signaling. Indeed, both HFE variants are able to interact with Alk3 but failed to increase Alk3 protein levels as detected on the cell surface of hepatocytes. However, the underlying mechanisms differ: although the H63D variant failed to inhibit Alk3 ubiquitination, the HFE C282Y mutant protected ALK3 from ubiquitination, similar to wild-type HFE. The authors speculate that the HFE C282Y mutant protein that does not reach the cell membrane sequesters Alk3 inside cells, thereby preventing Alk3 from trafficking to the cell surface.
Future work will need to address the mechanism of how HFE inhibits Alk3 ubiquitination and whether it interferes with a complex formed between the Smad ubiquitin regulatory factor (Smurf)1, BMP type I receptors, and the inhibitory Smads 6 and 7 (iSMADs). In addition, the impact of TfR2 in BMP/SMAD signaling, as well as the dynamics of complex formation involved in the sensing of systemic iron levels needs to be unraveled. Nevertheless, the present paper represents a milestone in the understanding of iron regulation and might even have an impact on drug development to treat HH by pharmacologically regulating ubiquitination of Alk3.
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In this issue of Blood, Myneni et al demonstrate a role for the A (transglutaminase) subunit of factor XIII (FXIII-A) in cell culture models of differentiation of preadipocytes to adipocytes. 1 This finding is potentially of great importance in light of recent genome-wide association and adipose tissue transcriptomic studies that implicated F13A1 in human obesity. 2 T he A subunit is the most enigmatic of the blood coagulation cascade participants. It has the characteristics of a cytoplasmic protein-no signal sequence, no asparaginelinked glycosylation, and no disulfides. 3 The mechanism for its secretion from cells is unknown. Once in the circulation, it binds to the B subunit, a proper plasma protein that is secreted classically by hepatocytes. 4 The subunits form an A 2 B 2 tetramer that circulates in plasma with a half-life of .1 week. On activation of blood coagulation, the A subunit is cleaved by thrombin, releasing an activation peptide and allowing A 2 to dissociate from the B subunits and become catalytically active (FXIII-A). FXIII-A covalently cross-links and stabilizes fibrin (see figure) . FXIII-A also cross-links circulating a 2 -antiplasmin and fibronectin into the fibrin meshwork; the former presumably protects the meshwork from incidental lysis, whereas the latter facilitates cellular ingrowth and subsequent healing. Deficiency of plasma FXIII from the lack of either the A or B subunit is associated with a distinctive spectrum of problems, including umbilical bleeding during the neonatal period, delayed soft tissue bruising, mucosal bleeding, life-threatening intracranial hemorrhage, poor wound healing, and recurrent miscarriages.
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Although the sources of circulating A 2 have not been explored thoroughly, megakaryocyte/platelets and monocyte/ macrophages likely are major players. Message for the A subunit, however, is found in a variety of cell types, raising the possibility that the A subunit may have cell type-specific functions independent of its role in blood coagulation. Myneni et al now describe a function for the A subunit synthesized during adipocyte differentiation. 1 They demonstrate that the A subunit forms an active transglutaminase that translocates to the cell surface and promotes assembly of fibronectin into extracellular matrix, which in turn causes the differentiating cells to proliferate more in response to insulin, a key differentiation agent, while slowing down differentiation and accumulation of lipid. Two experimental paradigms implicate the A subunit in these events: inhibition by a small molecule called NC9 that incorporates irreversibly into transglutaminases and a comparative study of fibroblasts cultured from mice in which the A subunit had been knocked out. Conditioning surfaces of culture tissues with adsorbed fibronectin has long been known to dampen adipocytic differentiation. 6 The present paper focuses on a more physiologically
